Development of UCCB01-144 as a new treatment for stroke.

A drug that protects brain cells during a stroke is about to be tested in humans for the first time. Stroke is a leading cause of death and long-term disability worldwide, yet treatment options remain limited. The only widely available drug, alteplase, must be given within a few hours and carries a risk of bleeding. UCCB01-144 works differently: it targets a protein called PSD-95 that sits inside the junctions between nerve cells. By blocking this protein, the drug appears to prevent a cascade of damage that follows a stroke, even when given hours later. Preclinical studies have shown strong results. If the Phase I trial confirms the drug is safe in humans, it could open the door to a new class of stroke treatments that are easier to administer and effective over a longer time window. That would change how emergency stroke care is delivered, potentially reducing the number of patients who die or are left permanently disabled. The research is not fundamental science—it is a direct push toward a new medicine, with a clear path to a Phase II trial if this first step succeeds.